• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IRON

    Disc Medicine Inc.

    Subscribe to $IRON
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Disc Medicine Inc.

    DatePrice TargetRatingAnalyst
    7/21/2025$86.00Buy
    Truist
    7/3/2025$85.00Overweight
    Morgan Stanley
    6/11/2025$89.00Strong Buy
    Raymond James
    2/27/2025Buy
    TD Cowen
    11/5/2024$85.00Equal-Weight → Overweight
    Morgan Stanley
    11/4/2024$66.00 → $110.00Outperform → Strong Buy
    Raymond James
    10/23/2024$89.00Buy
    Jefferies
    10/16/2024Sector Outperform
    Scotiabank
    8/22/2024$75.00Overweight
    Wells Fargo
    4/1/2024$40.00Strong Buy → Outperform
    Raymond James
    See more ratings

    Disc Medicine Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bitterman Kevin bought $8,000,028 worth of shares (222,223 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 8:00:05 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 5:27:54 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $3,000,024 worth of shares (83,334 units at $36.00) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    6/20/24 5:19:39 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Disc Medicine to Participate in Upcoming Investor Conferences

    WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences: Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 3rd at 10:55 a.m. ET. 2025 Wells Fargo Healthcare Conference on Thursday, September 4th at 4:30 p.m. ET. H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9th at 12:00 p.m. ET.Morgan Stanley 23rd Annual Global He

    8/27/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

    — Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease — — Pro forma cash and cash equivalents, assuming full exercise of common stock warrants, expected to fund planned operations into 2029 — — Industry expert Dan Baker, M.D., and OrbiMed representative Mona Ashiya, Ph.D., appointed to the Board of Directors — AUSTIN, TX and DURHAM, NC, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ:STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily rece

    8/26/25 6:30:00 AM ET
    $IRON
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update

    Company on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) under accelerated approval pathway in October 2025, supported by successful pre-NDA meetingExpect initial data from Phase 2 study of DISC-0974 in patients with anemia of myelofibrosis (MF) and multiple dose data from Phase 1b study of DISC-0974 in patients with anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD) in Q4 2025Initiated Phase 2 study of DISC-3405 in polycythemia vera (PV) with initial data expected in 2026Presented positive clinical data updates across the portfolio at the European Hematology Association (EHA) Annual Congress, including longer term efficacy and safety data from the

    8/7/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025

    WATERTOWN, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced positive feedback from its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned NDA submission for bitopertin in EPP. "At the pre-NDA meeting, we confirmed alignment with the agency on the expected timing and content of our NDA submission and, as a result, we are on track for a submission in October of this year," said John Quisel, J.D., Ph.D., Preside

    7/21/25 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Appoints Nadim Ahmed to its Board of Directors

    WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. "I am excited to welcome Nadim to Disc's Board of Directors at such a pivotal moment for the company," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "His track record of successful drug launches and deep expertise in hematological

    7/14/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

    Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

    6/12/25 7:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine to Participate in Upcoming Investor Conferences

    WATERTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5th at 10:30 a.m. ET. Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th at 1:20 p.m. ET. Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and

    5/28/25 4:01:00 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

    Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

    5/14/25 9:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

    WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20th at 9:00 am ET. A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event. About Disc Medicine Disc Medicine (NASDAQ:IRON) is

    5/13/25 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update

    Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPPPlan to initiate Phase 2 study of DISC-3405 in polycythemia vera (PV) in H1 2025Expect data readouts for DISC-0974 program in H2 2025, including initial results of Phase 2 anemia of myelofibrosis (MF) study and multiple dose data from Phase 1b anemia of non-dialysis dependent chronic kidney disease (NDD-CKD) studyStrong financial position supported by $259 million public offering in January 2025; ended Q1 with $695 million in cash, cash equivalents, and marketable securities, which is expected to

    5/7/25 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bitterman Kevin sold $139,576 worth of shares (2,287 units at $61.03) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/26/25 6:01:57 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $1,966,286 worth of shares (32,174 units at $61.11) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/15/25 7:23:46 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $24,075 worth of shares (395 units at $60.95) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/7/25 5:00:08 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $518,352 worth of shares (8,492 units at $61.04) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    8/1/25 4:32:51 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $2,616,390 worth of shares (42,870 units at $61.03) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    7/25/25 5:22:35 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bitterman Kevin sold $40,590 worth of shares (664 units at $61.13) (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    7/22/25 4:44:57 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Franchi Jean M. sold $119,829 worth of shares (2,031 units at $59.00), decreasing direct ownership by 3% to 63,499 units (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    7/18/25 4:51:40 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ahmed Nadim

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    7/16/25 5:56:09 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Ahmed Nadim

    3 - Disc Medicine, Inc. (0001816736) (Issuer)

    7/16/25 5:50:48 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Franchi Jean M. sold $115,000 worth of shares (2,000 units at $57.50), decreasing direct ownership by 3% to 65,530 units (SEC Form 4)

    4 - Disc Medicine, Inc. (0001816736) (Issuer)

    7/14/25 9:36:40 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Disc Medicine with a new price target

    Truist initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $86.00

    7/21/25 8:34:40 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Disc Medicine with a new price target

    Morgan Stanley resumed coverage of Disc Medicine with a rating of Overweight and set a new price target of $85.00

    7/3/25 8:01:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Disc Medicine with a new price target

    Raymond James resumed coverage of Disc Medicine with a rating of Strong Buy and set a new price target of $89.00

    6/11/25 7:53:18 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TD Cowen initiated coverage on Disc Medicine

    TD Cowen initiated coverage of Disc Medicine with a rating of Buy

    2/27/25 6:22:05 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Disc Medicine from Equal-Weight to Overweight and set a new price target of $85.00

    11/5/24 7:18:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine upgraded by Raymond James with a new price target

    Raymond James upgraded Disc Medicine from Outperform to Strong Buy and set a new price target of $110.00 from $66.00 previously

    11/4/24 9:40:15 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Disc Medicine with a new price target

    Jefferies initiated coverage of Disc Medicine with a rating of Buy and set a new price target of $89.00

    10/23/24 6:26:38 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Disc Medicine

    Scotiabank initiated coverage of Disc Medicine with a rating of Sector Outperform

    10/16/24 8:39:01 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Disc Medicine with a new price target

    Wells Fargo initiated coverage of Disc Medicine with a rating of Overweight and set a new price target of $75.00

    8/22/24 7:31:18 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine downgraded by Raymond James with a new price target

    Raymond James downgraded Disc Medicine from Strong Buy to Outperform and set a new price target of $40.00

    4/1/24 10:39:07 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Inc. Leadership Updates

    Live Leadership Updates

    View All

    Disc Medicine Appoints Nadim Ahmed to its Board of Directors

    WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. "I am excited to welcome Nadim to Disc's Board of Directors at such a pivotal moment for the company," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "His track record of successful drug launches and deep expertise in hematological

    7/14/25 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update

    Completed a successful end of Phase 2 meeting with the FDA for bitopertin in erythropoietic protoporphyria (EPP), reaching alignment on all proposed study parameters with the potential for accelerated approval based on existing dataPresented proof-of-mechanism data for Phase 1b trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) and anemia at the American Society of Nephrology (ASN) Kidney Week 2024Eight posters and an oral presentation across all three clinical-stage assets to be presented at the 66th American Society of Hematology (ASH) Annual Meeting and ExpositionStrong financial position ending Q3 with $487 million in cash, cash equivalents, and m

    11/12/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer

    WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas. "Rahul's experience is an ideal fit for Disc as we evolve in

    10/23/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

    WATERTOWN, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Steve Caffé, MD as the company's Chief Regulatory Officer. Dr. Caffé is an experienced biotech executive with significant expertise in global regulatory leadership across a wide range of therapeutic areas, including hematology, oncology, and rare diseases. "We are excited to welcome an executive as accomplished as Steve to Disc, where his depth of regulatory expertise and experience in glo

    9/19/24 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

    WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company's Chief Commercial Officer. Ms. Stephenson is an experienced biotech executive with significant expertise in commercial and strategic leadership, particularly in therapies for rare diseases, and will be responsible for all aspects of Disc's global commercialization strategy and execution. "We are delighted to welcome an accomplished leader such as Pam

    2/26/24 8:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

    Jean Franchi is an industry veteran and brings over 30 years of leadership experience in finance, investor relations, capital formation, and operations at both development and commercial-stage companiesJonathan Yu, previously Chief Business Officer at Disc, has been promoted to Chief Operating Officer WATERTOWN, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Jean Franchi as the company's Chief Financial Officer. Ms. Franchi will be responsible

    2/7/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

    WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON) ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that, after a distinguished 28-year career, including over 6 years at Disc, Brian MacDonald, MB, ChB, PhD, will be retiring from his role as Chief Innovation Officer. Dr. MacDonald plans to stay involved with Disc, transitioning from his current role to become Chair of Disc's Scientific Advisory Board. "We are incredibly grateful for all of Brian's exceptional contributions and leadership over the pa

    12/20/23 4:30:00 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Inc. Financials

    Live finance-specific insights

    View All

    Disc Medicine Presents Positive Clinical Data Updates Across Portfolio at the European Hematology Association (EHA) 2025 Annual Congress

    Positive updates across all programs, including longer term efficacy and safety data from the HELIOS open-label extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement to host a corporate update conference call on Monday, June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematolo

    6/12/25 7:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2025 Congress

    Poster presentations across all programs, including data from HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria (EPP), additional durability data from Phase 1b study of DISC-0974 in anemia of myelofibrosis (MF), and additional data from DISC-3405 studies in healthy volunteersManagement will host a corporate update conference call on Monday June 16 at 8:00 am ET / 2:00 pm CEST WATERTOWN, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that

    5/14/25 9:30:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

    Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trialsAchieved regulatory alignment on APOLLO post-marketing confirmatory trial design and on track to initiate trial by mid-year 2025Aligned on average monthly time in light without pain during the last month of the 6-month treatment period and percent change from baseline in whole-blood metal-free PPIX after 6 months of treatment as coprimary endpoints for confirmatory trialManagement will host a conference call on Tuesday, Ja

    1/21/25 7:45:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

    WATERTOWN, Mass., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its Type C meeting on bitopertin in EPP with the U.S. Food and Drug Administration (FDA). The conference call will be held on Tuesday, January 21, at 8:00 am EST. Conference Call Information Please register for the event on the Events and Presentations page of Disc's website at https://ir.discmedicine.com/. About Bitopertin Bitopertin is an investigationa

    1/20/25 7:00:00 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

     Positive updates across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement hosted a conference call during the ASH meeting on Sunday, December 8 discussing highlights of the presented data and next steps for the company WATERTOWN, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ASH 2024 annual meeting in San Diego, C

    12/9/24 12:00:00 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

    Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indicationsManagement will host a conference call during the ASH meeting on Sunday, December 8 at 9:00pm EST / 6:00pm PST WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announ

    11/5/24 9:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

    Alignment with the FDA across all proposed study parameters, providing a clear development path to registrationAgreement on proposed primary endpoint of average monthly time in sunlight during the last month following a 6-month treatment periodPotential for accelerated approval based on existing data and utilizing reduction of PPIX as a surrogate endpointPlan to initiate APOLLO trial, a 6-month study of a 60 mg dose of bitopertin in EPP and XLP patients ages 12+ by mid-2025Management will host a conference call on Monday, November 4 at 8:00 am EST WATERTOWN, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on th

    11/4/24 7:50:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

    WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, will host a conference call to discuss feedback received from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA). The conference call will be held on Monday, November 4, at 8:00 am EST. Conference Call Information Please register for the event on the Events and Presentations page of Disc's website at https://ir.discmedicine.com/. About Bitopertin Bitopertin is an investigational, clinical-s

    11/1/24 4:01:00 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

    Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but did not meet statistical significance compared to placeboDose-dependent reductions in the rate of phototoxic reactions with pain, with statistical significance at the 60 mg dose group compared to placeboDose-dependent improvements in the Patient Global Impression of Change (PGIC), with statistical significance at the 60 mg dose group compared to placeboInvestor webcast at 8:30 am ET to discuss top-line data

    4/1/24 8:00:00 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

    Updated data from BEACON continued to demonstrate significant, consistent reductions in protoporphyrin IX (PPIX) > 40% and improvements in sunlight toleranceRobust and consistent improvements across all measures of sunlight tolerance, including >3x improvement over historical control of precedented pivotal endpointBitopertin was generally well-tolerated with stable hemoglobin at both dose levelsEarlier today, Disc also announced initial positive data from the phase 1b study of DISC-0974 in myelofibrosis patients with anemia, demonstrating improvements in hemoglobin and reductions in transfusion burden WATERTOWN, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a

    12/11/23 8:30:00 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Inc. SEC Filings

    View All

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/22/25 4:29:56 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/22/25 4:25:35 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Disc Medicine Inc.

    SCHEDULE 13D/A - Disc Medicine, Inc. (0001816736) (Subject)

    8/15/25 7:16:36 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/14/25 4:24:27 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/14/25 4:16:25 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/13/25 4:26:10 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Disc Medicine Inc.

    144 - Disc Medicine, Inc. (0001816736) (Subject)

    8/13/25 4:24:26 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Disc Medicine Inc.

    SCHEDULE 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    8/12/25 10:34:25 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Disc Medicine Inc.

    SCHEDULE 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    8/7/25 10:16:27 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Disc Medicine Inc.

    10-Q - Disc Medicine, Inc. (0001816736) (Filer)

    8/7/25 8:40:50 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Disc Medicine Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 5:44:55 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Disc Medicine Inc.

    SC 13G/A - Disc Medicine, Inc. (0001816736) (Subject)

    11/14/24 4:33:10 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Disc Medicine Inc.

    SC 13G - Disc Medicine, Inc. (0001816736) (Subject)

    11/8/24 10:52:39 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Disc Medicine Inc.

    SC 13G - Disc Medicine, Inc. (0001816736) (Subject)

    6/25/24 10:06:26 AM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Disc Medicine Inc.

    SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)

    6/20/24 5:15:31 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Disc Medicine Inc.

    SC 13D/A - Disc Medicine, Inc. (0001816736) (Subject)

    6/20/24 4:01:56 PM ET
    $IRON
    Biotechnology: Pharmaceutical Preparations
    Health Care